The company could be on the verge of turning the tide in the battle over weight loss drugs.It's no secret that Novo Nordisk (NVO -1.69%) and Eli Lilly (LLY 1.52%) are toughing it out in the battle of the weight loss drug market. It's also not lost on many investors that Eli Lilly's obesity drug, Zepbound, is winning market share away from Novo Nordisk's offering, Wegovy. Why Eli Lilly is winningDespite Wegovy being approved by the Food and Drug Administration (FDA) to treat obesity first in 2021 and Zepboun ...